ISR Articles
-
3 Year Rolling Average – Phase I Service Provider Customer Loyalty
5/12/2020
In Q4, 2019, ISR asked sponsors who outsource phase I trials to better understand customer loyalty. CRO loyalty is computed as an index that consists of likelihood to recommend, likelihood to use again, and overall satisfaction. The data below show companies with twenty or more user ratings over the past 3 years and an industry average derived from all CROs included in the research.
-
Most Important Capabilities For Pharmacovigilance Services
4/16/2020
In Q4, 2019, ISR asked outsourcers of drug safety / pharmacovigilance services about the most important capabilities when choosing a pharmacovigilance provider. Regulatory compliance tops the list as the most important capability for service provider selection. Half of respondents picked it among their top five capabilities and 15% of respondents selected it as the most important capability.
-
ISR's Contract Manufacturing Databook
4/1/2020
It can be difficult to find industry specific, easy to interpret, trustworthy market data. Read the available eBook to discover free drug development and manufacturing facts, figures, and expert perspectives.
-
Preferred Provider Use Among Bioanalytical Lab Outsourcers
3/13/2020
In Q3, 2019, ISR asked outsourcers of bioanalytical lab services about their organization’s use of preferred providers. The data show use of preferred providers is common practice when outsourcing bioanalytical lab work, 88% currently use a preferred lab for preclinical services and 90% currently use a preferred lab for clinical services. On average, respondents indicate that their company currently has 2.3 preferred labs for preclinical services and 2.6 preferred labs for clinical lab work. For more information, follow the link to the Bioanalytical Labs Market Dynamics and Service Provider Performance report preview.
-
Improving Clinical Logistics Outsourcing Relationships
2/12/2020
In Q3, 2019, ISR asked 100 outsourcers of clinical logistics about several different scenarios that could potentially improve outsourcing relationships. Two scenarios were considered Very Likely – Likely to improve relationships by three-quarters of respondents: Improved technology integration and improvements to project management from both the sponsor and service provider.
-
Top 5 Selection Attributes Gaining Importance For Outsourced Bioanalytical Lab Services
1/14/2020
In Q3, 2019, ISR asked outsourcers of bioanalytical lab services about their thoughts on 22 selection qualities that have become more important in the past year when choosing a provider for bioanalytical lab services. Assay development expertise (46%), and Technical expertise/experts (44%) top the list of lab qualities that are increasing in importance.
-
Clinical Materials Distribution by Location
11/11/2019
In Q3, 2019, ISR asked outsourcers of clinical logistics about the proportion of clinical materials distributed to the following locations: trial sites, depots, warehouses, and directly to patients. The data show the majority of clinical materials are currently sent to trial sites (53%) and that only 5% are sent directly to patients. However, over the next three years, respondents anticipate the proportion of clinical materials going directly to patients will double.
-
IRB Performance And Best Practices In Site Start-up: Review Of Two Recent Market Research Reports
10/30/2019
ISR will review findings from two recent, high-profile pieces of market research. One details the performance of specific IRBs in the clinical development space across such metrics as timeliness and responsiveness of protocol review and local IRB/regulatory knowledge. This report also highlights trends impacting how companies interact with IRBs—mainly the need for improved use of technology. The other report is an in-depth look into what CROs and sponsors are doing, what’s working, what’s not working, and what’s next in their quest to increase the efficiency and effectiveness of site start-up activities in clinical development.
-
2018-2023 Edition Of The CRO Market Size Projections
8/16/2019
Since ISR first put out our CRO Market Size projections, there have been several other reports produced, with surprisingly similar figures. Some of these have future growth rates for the CRO market as high as >10% and some have them as low as ~5%. We are somewhere in the middle. ISR is projecting a CAGR from 2018 to 2023 of 7.5%. Remember that a lot can (and will) change between now and 2023, but we believe the fundamentals are in place for a growing outsourced clinical development market.
-
Finding A Glass Slipper Service Provider To Fit Your Phase II/III Outsourcing Needs
Your checklist of niche needs is long, including a complex indication, specialized patient recruitment, and risk-based monitoring. You have some ideas about which CROs you think would fit the bill for outsourcing needs, but it will be a difficult decision. And so the provider selection process begins.